Genentech, MedImmune end patent rift over Synagis

06/11/2008 | Bloomberg Businessweek · TheStreet.com

Genentech and MedImmune have reached an agreement to resolve a patent dispute over motavizumab and Synagis, a respiratory drug. The settlement allows MedImmune -- a unit of AstraZeneca PLC -- to receive licenses for selected pipeline products under a patent Genentech co-owns with City of Hope National Medical Center.

View Full Article in:

Bloomberg Businessweek · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC